Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $58,785.30 in Stock

by · The Cerbat Gem

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) insider David Malcom Rodman sold 2,170 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.09, for a total value of $58,785.30. Following the completion of the transaction, the insider directly owned 51,384 shares of the company’s stock, valued at approximately $1,391,992.56. This trade represents a 4.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

  • On Thursday, July 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.30, for a total transaction of $65,781.30.
  • On Wednesday, June 17th, David Malcom Rodman sold 4,584 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $114,600.00.
  • On Monday, June 15th, David Malcom Rodman sold 9,890 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $23.81, for a total transaction of $235,480.90.
  • On Friday, June 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $23.93, for a total transaction of $151,931.57.
  • On Wednesday, June 10th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $54,250.00.
  • On Monday, May 18th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.55, for a total value of $11,488.35.

Mineralys Therapeutics Trading Down 1.0%

Shares of MLYS stock traded down $0.28 during trading hours on Wednesday, reaching $27.05. The company’s stock had a trading volume of 1,396,596 shares, compared to its average volume of 628,579. Mineralys Therapeutics, Inc. has a fifty-two week low of $12.59 and a fifty-two week high of $47.65. The firm’s 50 day simple moving average is $26.42 and its 200-day simple moving average is $27.60.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.30). Equities analysts predict that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

More Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

  • Positive Sentiment: Regulatory milestone remains on track: The company reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational treatment for hypertension, and said commercial launch preparations are progressing in anticipation of approval. Mineralys second-quarter results and corporate update
  • Positive Sentiment: Financial flexibility improved: Management highlighted a strong cash position with funding expected to support operations into 2028. Strategic financing initiatives and the repurchase of the Tanabe royalty obligation also strengthen the long-term economics of lorundrostat by reducing a future royalty burden. Mineralys launch readiness and cash runway
  • Positive Sentiment: New medical leadership: Mineralys appointed cardiovascular medicine executive Dr. Terry Ferguson as chief medical officer. He will oversee medical strategy and late-stage clinical activities ahead of the potential lorundrostat launch. Mineralys appoints chief medical officer
  • Neutral Sentiment: Short-interest data offered little signal: Reported short interest was zero shares, with a zero-day days-to-cover ratio, suggesting the data does not indicate meaningful short-selling pressure.
  • Negative Sentiment: Quarterly loss missed expectations sharply: Mineralys reported a second-quarter loss of $2.85 per share, compared with the analyst consensus estimate of a $0.55 loss. The sizable variance may be weighing on the stock, although the company remains focused on its pre-commercial development and launch activities. Mineralys second-quarter earnings call transcript

Hedge Funds Weigh In On Mineralys Therapeutics

A number of hedge funds have recently modified their holdings of the business. Navalign LLC acquired a new position in shares of Mineralys Therapeutics in the fourth quarter worth approximately $33,000. KBC Group NV acquired a new stake in Mineralys Therapeutics during the 1st quarter valued at approximately $33,000. Royal Bank of Canada boosted its stake in shares of Mineralys Therapeutics by 262.3% in the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after purchasing an additional 1,107 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Mineralys Therapeutics by 1,845.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock valued at $76,000 after purchasing an additional 1,993 shares during the last quarter. Finally, FNY Investment Advisers LLC raised its stake in Mineralys Therapeutics by 400.0% during the second quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company’s stock worth $67,000 after buying an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on MLYS. Jefferies Financial Group reiterated a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. TD Cowen initiated coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, HC Wainwright reiterated a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $49.33.

Check Out Our Latest Analysis on MLYS

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Recommended Stories